tiprankstipranks
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC

Oric Pharmaceuticals (ORIC) AI Stock Analysis

Compare
328 Followers

Top Page

OR

Oric Pharmaceuticals

(NASDAQ:ORIC)

42Neutral
Oric Pharmaceuticals scores low overall due to its development stage characteristics, including no revenue generation and negative cash flows. While the company shows strong financial resilience with substantial cash reserves and no debt, its technical indicators signal weakness. Recent corporate events suggest strategic growth, but the lack of positive valuation metrics remains a significant concern.
Positive Factors
Clinical Development
The initiation of pivotal Phase 3 trials for ORIC-944 and ORIC-114 is expected in 2026, indicating progress in the clinical development of these drugs.
Financial Stability
ORIC's cash runway now extends into 2027, providing financial stability and supporting continued development efforts.
Negative Factors
Clinical Development Risks
Risks include potential inability to advance ORIC-114 and ORIC-944 in clinical development and delays in moving into pivotal trials.

Oric Pharmaceuticals (ORIC) vs. S&P 500 (SPY)

Oric Pharmaceuticals Business Overview & Revenue Model

Company DescriptionOric Pharmaceuticals (ORIC) is a biopharmaceutical company focused on discovering and developing innovative treatments for cancer. The company operates primarily in the biotechnology sector, leveraging its expertise in oncology to address mechanisms of therapeutic resistance. Its core products are centered around developing small molecule drugs designed to counteract resistance in cancer treatments, thereby improving the efficacy of existing therapies and extending patient survival rates.
How the Company Makes MoneyOric Pharmaceuticals generates revenue primarily through the development and commercialization of its drug candidates. The company seeks to monetize its pipeline by advancing its proprietary compounds through clinical trials and obtaining regulatory approval, which then allows it to either market these drugs directly or license them to larger pharmaceutical companies. Key revenue streams include potential milestone payments, royalties from partnerships with larger pharmaceutical companies, and future product sales upon successful drug approval. Oric may also engage in strategic collaborations and partnerships to co-develop or out-license its technologies, which can provide upfront payments and shared development costs, contributing to its revenue.

Oric Pharmaceuticals Financial Statement Overview

Summary
Oric Pharmaceuticals shows typical characteristics of a biotechnology firm in the development stage, with no revenue generation, negative profitability metrics, and reliance on equity and financing to fund operations. While the balance sheet demonstrates financial stability through high equity and cash reserves, the lack of revenue and ongoing cash consumption present significant risks.
Income Statement
10
Very Negative
Oric Pharmaceuticals has consistently reported zero revenue over the years, indicating that the company is still in the development phase typical for biotechnology firms. The persistent net losses and negative EBIT and EBITDA highlight ongoing operational challenges without any revenue to offset costs. This results in minimal profitability and growth metrics.
Balance Sheet
60
Neutral
The company maintains a strong equity position with zero total debt, resulting in a favorable debt-to-equity ratio. The high equity ratio indicates financial stability, while the substantial cash reserves suggest good liquidity to support ongoing operations and development activities. However, the continuous net losses may eventually impact equity if no revenue generation occurs.
Cash Flow
40
Negative
Operating cash flows have been consistently negative, reflecting the company's cash consumption due to ongoing operations without revenue inflows. The company has managed to maintain liquidity through financing activities, as seen in positive financing cash flows. However, free cash flow remains negative, highlighting the need for continual financing to sustain operations.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.000.000.00
Gross Profit
0.00-1.03M-966.00K-897.00K-970.00K
EBIT
-142.90M-110.78M-91.77M-78.87M-74.19M
EBITDA
-142.90M-109.75M-91.77M-77.97M-74.19M
Net Income Common Stockholders
-127.85M-100.70M-91.48M-77.68M-97.27M
Balance SheetCash, Cash Equivalents and Short-Term Investments
255.96M208.19M206.27M236.98M293.60M
Total Assets
274.14M252.01M247.18M298.64M299.00M
Total Debt
3.18M10.21M2.66M1.93M0.00
Net Debt
-59.41M-13.17M-64.18M-224.08M-78.45M
Total Liabilities
31.02M27.92M24.83M25.67M9.22M
Stockholders Equity
243.12M224.09M222.35M272.98M289.78M
Cash FlowFree Cash Flow
-112.66M-86.54M-77.22M-60.48M-45.94M
Operating Cash Flow
-112.66M-85.69M-75.14M-59.54M-45.27M
Investing Cash Flow
22.14M-43.40M-109.25M158.44M-215.96M
Financing Cash Flow
126.55M85.66M25.62M49.13M250.51M

Oric Pharmaceuticals Technical Analysis

Technical Analysis Sentiment
Negative
Last Price7.79
Price Trends
50DMA
9.14
Negative
100DMA
9.13
Negative
200DMA
9.26
Negative
Market Momentum
MACD
-0.44
Negative
RSI
43.08
Neutral
STOCH
66.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORIC, the sentiment is Negative. The current price of 7.79 is below the 20-day moving average (MA) of 7.85, below the 50-day MA of 9.14, and below the 200-day MA of 9.26, indicating a bearish trend. The MACD of -0.44 indicates Negative momentum. The RSI at 43.08 is Neutral, neither overbought nor oversold. The STOCH value of 66.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ORIC.

Oric Pharmaceuticals Risk Analysis

Oric Pharmaceuticals disclosed 95 risk factors in its most recent earnings report. Oric Pharmaceuticals reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Oric Pharmaceuticals Peers Comparison

Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
$5.14B59.3610.34%473.02%1620.44%
59
Neutral
$3.85B-31.41%49.59%24.92%
53
Neutral
$897.61M-50.50%4.28%
49
Neutral
$6.87B0.03-54.93%2.50%24.65%-2.90%
44
Neutral
$115.22M-53.54%145.37%57.01%
42
Neutral
$553.30M-54.73%7.15%
42
Neutral
$107.89M-54.21%-78.55%-0.92%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ORIC
Oric Pharmaceuticals
7.79
-6.89
-46.93%
FATE
Fate Therapeutics
0.94
-6.10
-86.65%
ADAP
Adaptimmune Therapeutics
0.45
-1.02
-69.39%
ZLAB
Zai Lab
38.20
20.12
111.28%
KRYS
Krystal Biotech
179.38
10.85
6.44%
REPL
Replimune Group
11.66
3.38
40.82%

Oric Pharmaceuticals Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Oric Pharmaceuticals Expands Equity Incentive Plan for Growth
Positive
Mar 14, 2025

On March 11, 2025, Oric Pharmaceuticals’ Board of Directors approved an amendment to the 2022 Inducement Equity Incentive Plan, increasing the shares reserved for issuance by 1,100,000, totaling 2,250,000 shares. This move, made without stockholder approval under Nasdaq rules, aims to attract new employees and facilitate mergers or acquisitions, aligning with the company’s strategic growth and talent acquisition objectives.

Product-Related AnnouncementsBusiness Operations and Strategy
Oric Pharmaceuticals to Present at J.P. Morgan Conference
Positive
Jan 13, 2025

ORIC Pharmaceuticals plans to present an updated corporate presentation at the J.P. Morgan Healthcare Conference, highlighting its progress in advancing two lead programs, ORIC-114 and ORIC-944, towards pivotal studies. With a strong financial position, the company is well-positioned to continue its development pipeline, targeting new investigational new drug candidates and anticipating significant data milestones in the upcoming years, which could strengthen its industry positioning and impact stakeholders by addressing unmet needs in cancer treatment.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.